Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 40

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 40
---
──

  statements about the Company made in the         

  statements made about drug pricing and other      

  changes in government regulations or patent  
  decisions;                                   
 ───────────────────────────────────────────────

  developments by our licensees; and  

  general market conditions and other factors,               

These factors and any corresponding price fluctuations may materially
and adversely affect the market price of our ordinary shares and ADSs, and result in substantial losses by our investors. See also Risk
Factors - Risks Related to our Ordinary Shares and ADSs - “ Our business, operating results
and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with
respect to financial institutions and associated liquidity risk. ”

Additionally, market prices for securities of biotechnology and pharmaceutical companies
historically have been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations
for reasons unrelated to the operating performance of any one company. Following periods of market volatility, shareholders have often
instituted securities class action litigation, and in the past, we have been party to securities class action litigations. See “ Item
8. A - Financial Information - Legal Proceedings” for additional information. Such securities litigation or any additional
securities litigation could have a substantial cost and divert resources and attention of management from our business, even if we are
successful.

Our ordinary shares are traded on the TASE and our ADSs are listed
on Nasdaq. Trading in our securities on these markets takes place in different currencies (dollars on Nasdaq and NIS on the TASE), and
at different times (resulting from different time zones, different trading days and different public holidays in the United States and
Israel). The trading prices of our securities on these two markets may differ due to these factors, the factors listed above, or other
factors. Any decrease in the price of our securities on one of these markets could cause a decrease in the trading price of our securities
on the other market.

Future sales of our ordinary
shares or ADSs could reduce the market price of our ordinary shares and ADSs.

Substantial sales of our ordinary shares or ADSs, either on the
TASE or on Nasdaq, may cause the market price of our ordinary shares or ADSs to decline. Sales by us or our securityholders of substantial
amounts of our ordinary shares or ADSs, or the perception that these sales may occur in the future, could cause